The stock of Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has decreased by -1.40 when compared to last closing price of 26.48. Despite this, the company has experienced a -9.02% fall in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-13 that While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn’t received the same fervor.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Right Now?
ARWR has 36-month beta value of 0.73. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ARWR is 117.62M, and currently, short sellers hold a 7.82% ratio of that float. The average trading volume of ARWR on April 05, 2024 was 1.54M shares.
ARWR’s Market Performance
The stock of Arrowhead Pharmaceuticals Inc. (ARWR) has seen a -9.02% decrease in the past week, with a -23.39% drop in the past month, and a -18.33% fall in the past quarter. The volatility ratio for the week is 4.10%, and the volatility levels for the past 30 days are at 4.97% for ARWR. The simple moving average for the past 20 days is -9.61% for ARWR’s stock, with a -12.86% simple moving average for the past 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with BofA Securities repeating the rating for ARWR by listing it as a “Buy.” The predicted price for ARWR in the upcoming period, according to BofA Securities is $29 based on the research report published on December 04, 2023 of the previous year 2023.
Citigroup, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $33. The rating they have provided for ARWR stocks is “Neutral” according to the report published on September 19th, 2023.
ARWR Trading at -15.17% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.54% of loss for the given period.
Volatility was left at 4.97%, however, over the last 30 days, the volatility rate increased by 4.10%, as shares sank -26.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.86% lower at present.
During the last 5 trading sessions, ARWR fell by -9.02%, which changed the moving average for the period of 200-days by -26.24% in comparison to the 20-day moving average, which settled at $28.42. In addition, Arrowhead Pharmaceuticals Inc. saw -14.67% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Hamilton James C, who sale 6,000 shares at the price of $28.03 back on Apr 01 ’24. After this action, Hamilton James C now owns 204,851 shares of Arrowhead Pharmaceuticals Inc., valued at $168,180 using the latest closing price.
Lu Hongbo, the Director of Arrowhead Pharmaceuticals Inc., purchase 1,000 shares at $27.50 during a trade that took place back on Mar 20 ’24, which means that Lu Hongbo is holding 33,680 shares at $27,500 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -1.65 for the present operating margin
- 0.92 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc. stands at -1.63. The total capital return value is set at -0.53. Equity return is now at value -110.45, with -39.11 for asset returns.
Based on Arrowhead Pharmaceuticals Inc. (ARWR), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at -1.65. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is -14.36.
Currently, EBITDA for the company is -188.16 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 18.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.73.
Conclusion
To put it simply, Arrowhead Pharmaceuticals Inc. (ARWR) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
